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Abstract
Chronic alcohol exposure can lead to alcoholic liver dis-
ease, including hepatitis, cirrhosis and hepatocellular 
carcinoma, and chronic inflammation can simultaneously 
cause systemic medical illness. Recent evidence suggests 
that alcoholic liver disease is a predictor for liver-related 
diseases, cardiovascular disease, immunologic disease, 
and bone disease. Chronic inflammation in alcoholic liver 
disease is mediated by a direct inflammatory cascade 
from the alcohol detoxification process and an indirect in-
flammatory cascade in response to gut microflora-derived 
lipopolysaccharides (LPS). The pathophysiology of alco-
holic liver disease and its related systemic illness is char-
acterized by oxidative stress, activation of the immune 
cascade, and gut-liver interactions. Integrative therapeu-
tic strategies for alcoholic liver disease include abstaining 
from alcohol consumption; general anti-inflammatories 
such as glucocorticoid, pentoxifylline, and tumour necro-
sis factor-α antagonist; antioxidants such as N- acetylcys-
teine; gut microflora and LPS modulators such as rifaxi-
min and/or probiotics. This review focuses on the impact 
of chronic liver inflammation on systemic health problems 
and several potential therapeutic targets.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Beyond the natural course in the liver, alco-
holic liver disease can be implicated in many health 
problems that affect the quality of life and disease 
progression. Evidence suggests that alcoholic liver 
disease is a predictor for liver-related diseases, car-
diovascular disease, immunologic disease, and bone 
disease. Chronic inflammation in alcoholic liver disease 
and related systemic illness is mediated by a direct 
response to alcohol and an indirect inflammatory re-
sponse. Alcoholic liver disease should be considered 
from the perspective of chronic inflammation. Accord-
ingly, integrative therapeutic strategies including anti-
inflammatory targeting are needed for alcohol-induced 
liver inflammation management and prevention of sys-
temic medical problems.
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INTRODUCTION
Chronic alcohol consumption is a major risk factor for 
chronic liver disease worldwide. Cardinal features of  al-
coholic liver disease include simple fatty liver, alcoholic 
hepatitis, fibrosis or, more seriously, cirrhosis and hepa-
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tocellular carcinoma. Alcohol has been recognized as a 
true hepatotoxin, an agent able to cause liver damage, 
for many years[1]. Although abstaining from alcohol is 
the primary recommendation for managing alcoholic liv-
er disease, the chronic features of  alcoholic liver disease 
and its progression can affect a patient’s attitude toward 
consumption. Alcohol is an important cause of  hepato-
cellular carcinoma in Korea in addition to the hepatitis B 
virus and the hepatitis C virus[2]. Additionally, up to 48% 
of  cirrhosis-related deaths have been associated with al-
cohol in the United States[3].
Recent evidence has determined that inflammation 
is closely linked with development of  alcoholic liver 
disease[3-7]. Acute inflammation as a defense against 
noxious stimuli is very important for homeostasis in 
the body, whereas chronic exposure to an agent that 
induces inflammation may cause a dysregulated or un-
resolved inflammatory response, which causes chronic 
inflammation. Finally, various inflammatory components 
can influence systemic medical conditions. The major 
sources of  chronic low-grade inflammation in alcoholic 
liver disease are categorized as follows: a direct inflam-
matory cascade from the alcohol detoxification process 
and an indirect inflammatory cascade in response to gut 
microflora-derived lipopolysaccharides (LPS).
The liver plays a key role in detoxifying alcohol and 
its related toxic products and is also responsible for im-
munologic effects. However, chronic alcohol consump-
tion can lead to alcoholic liver disease and simultaneous 
systemic medical illness because of  chronic inflamma-
tion. Beyond the natural course in the liver, alcoholic 
liver disease can be implicated in many health problems 
that affect the quality of  life and disease progression. 
Therefore, alcoholic liver disease should be considered 
from the perspective of  chronic inflammation. This 
review focuses on the impact of  chronic liver inflamma-
tion on systemic health problems and several potential 
therapeutic targets.
CARDIOVASCULAR DISEASE
Emerging evidence suggests that alcoholic liver disease 
predicts not only liver-related diseases, but also ath-
erosclerotic cardiovascular disease (CVD). Recent data 
suggest that some pathogenic mechanisms are involved 
in atherosclerotic CVD. In patients with alcoholic liver 
disease, alcohol, acetaldehyde, and excessive free fatty 
acids (FFA) in hepatocytes generate an excess of  reac-
tive oxygen species (ROS). This formation leads to 
lipid peroxidation, cytokine production, and hepatic 
inflammation[8], which contribute to a higher oxidative-
inflammatory response. Thus, alcoholic liver disease may 
actively involve chronic low-grade inflammation in the 
arterial wall[9]. Moreover, pro-inflammatory cytokines 
such as tumor necrosis factor-α (TNF-α), interleukin-6 
(IL-6), interleukin-8 (IL-8), and interleukin-17 (IL-17) 
are produced by Kupffer cells in the liver in response 
to LPS, which, in turn, play a key role in inducing acute 
phase reactants in the liver, such as C-reactive protein 
(CRP), ferritin, and amyloid A[10,11]. These inflammatory 
cascades can also synergistically or interactively contribute 
to arterial inflammation. Indeed, several epidemiologic 
studies have shown that various inflammatory markers, 
such as TNF-α and CRP, are elevated in patients with al-
coholic liver disease[12-14]. Furthermore, chronic low-grade 
inflammation plays a crucial role in regulating arterial wall 
tone by affecting the release of  nitric oxide (NO) and 
endothelin-1[15,16]. These cascades may cause endothelial 
dysfunction and alter arterial elastic properties, leading to 
arterial stiffness. In addition, when a hepatic cell is dam-
aged, hepatic stellate cells also secrete angiotensin Ⅱ[17], a 
major pro-atherogenic and vasoconstrictive peptide that 
acts on the arterial wall. The overproduction of  hema-
tostatic factors such as plasminogen activator inhibitor-1 
(PAI-1) may have a direct atherogenic effect on blood 
vessels[18] in patients with alcoholic liver disease. Lastly, 
chronic alcohol consumption has a tendency for in-
creased plasma homocysteine levels, albeit the results are 
inconsistent according to amount and types of  alcoholic 
beverage consumed, or underlying diseases[19]. However, 
hyperhomocysteinemia induced by chronic alcohol con-
sumption may be one of  the important risk factors for 
CVD[20,21].
IMMUNOLOGIC DISEASE
Recent research has shown that alcoholic liver disease 
may alter immune regulation, which can lead to immuno-
deficiency and autoimmunity[22]. Additionally, individuals 
with chronic alcohol consumption are more susceptible 
to bacterial pneumonia and septicemia[23-25]. There is also 
an increased incidence of  pulmonary tuberculosis or 
human immunodeficiency virus (HIV) in patients with 
alcoholic liver disease[26-28]. In addition, less common 
infectious diseases such as meningitis, diphtheria, lung 
abscess, or cellulitis are more prevalent in alcoholic liver 
disease[27].
Alcoholic hepatitis and alcoholic liver cirrhosis have 
been associated with autoimmune properties[22]. Liver 
function in patients with alcoholic hepatitis can decrease 
for several weeks (at least two weeks) after abstinence 
from alcohol, and resuming drinking after recovering 
from alcoholic hepatitis can lead to more severe alco-
holic hepatitis. In this regard, autoantibodies against the 
liver may be an important cause of  the liver damage and 
scarring in alcoholic liver disease.
Other autoimmune diseases or allergic reactions are 
also seen in alcoholic liver disease. Immunoglobulin A 
(IgA) has been found in skin and kidney deposits as 
well as the liver in many patients with alcoholic liver 
disease[29]. Also, alcohol consumption contributes to im-
munoglobulin E (IgE)-mediated reactions in susceptible 
humans, such as individuals with food allergies or asth-
ma[30]. Chronic alcohol use has been found to increase 
total IgE level[30-32]. Therefore, understanding altered 
immunity and cytokines in alcoholic liver disease can be 
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important for assessing potential immunologic risk and 
could provide insight into therapeutic targets.
BONE DISEASE
Hepatic osteodystrophy is abnormal bone metabolism 
that has been identified in association with chronic liver 
disease, including such conditions as osteopenia, osteo-
porosis, and osteomalacia. The prevalence of  osteopenia 
in patients with alcoholic liver disease is between 34% 
and 48%, and the prevalence of  osteoporosis is between 
11% and 36%[33-35]. However, osteomalacia has rarely 
been confirmed in patients with chronic liver disease and 
low vitamin D level[36,37].
Bone is a dynamic tissue that is remodeled through 
constant bone resorption and formation. Bone turnover 
accounts for up to 15% of  the annual renovation of  
total bone mass[38]. Decreased bone density, commonly 
seen in hepatic osteodystrophy, results from decreased 
bone formation or increased bone resorption. Bone 
mineral density, measured by dual energy X-ray absorp-
tiometry, is reported with a Z score and T score; the 
former is used to compare the patient’s bone mineral 
density with an age-matched mean value, and the latter 
is used to compare the bone mineral density with that of  
healthy young individuals. Osteopenia is identified when 
a T score ranges from -1.0 to -2.5, and osteoporosis is 
defined by a T score < 2.5. Osteomalacia is characterized 
by abnormal bone matrix mineralization, which can be 
confirmed by bone biopsy. These metabolic bone diseas-
es are very common and can be important complications 
in patients with alcoholic liver disease. Although the 
mechanism of  metabolic bone diseases remains com-
plex and multifactorial, osteoclastogenic inflammatory 
cytokines, such as interleukin 1 (IL-1) and TNF-α, have 
been known to have a key role in the pathogenesis of  
bone metabolic disease that is related to alcoholic liver 
disease[39]. Early assessment and therapeutic intervention 
in patients with hepatic osteodystrophy can be important 
for minimizing future fracture risk and maintaining the 
quality of  life.
PATHOPHYSIOLOGY
Oxidative stress
It is known that alcohol increases ROS, which are chemi-
cally reactive molecules that can damage various cellular 
components such as proteins, lipids, or deoxyribonucleic 
acid (DNA)[40]. Moreover, acetaldehyde, an intermediate 
alcohol metabolite, is a highly reactive compound and is 
highly toxic to hepatocytes, promotes glutathione deple-
tion, lipid peroxidation, and mitochondrial damage[41-42]. 
Evidence suggests that oxidative stress can contribute to 
the development of  alcoholic liver disease and has been 
associated with various major diseases including cardio-
vascular diseases, type 2 diabetes, neurodegenerative dis-
ease, and carcinogenesis[43-46].
Although multiple mechanisms are involved in alco-
hol-related ROS production, cytochrome P450 E21 and 
the mitochondrial electron transport chain are impor-
tant targets[40,47,48]. Moreover, alcohol-derived ROS may 
directly trigger the systemic inflammatory response[49]. 
ROS could activate nuclear factor kappa B (NF-κB), 
which leads to production of  inflammatory cytokines 
such as TNF-α. Alcohol-derived ROS may play a role in 
initiating a vicious cycle via the liver cell damage mecha-
nism with additional inflammatory cytokines and ROS 
production[50]. Therefore, alcohol-derived ROS may be 
important for understanding systemic inflammation ac-
companied with alcoholic liver disease.
Activation of immunity
As described above, individuals with chronic alcohol 
consumption are more susceptible to immunodeficiency 
and autoimmunity. Understanding altered innate and 
acquired immunity in alcoholic liver disease may be im-
portant for assessing the potential risk of  opportunistic 
infections and allergic diseases such as food allergies and 
bronchial asthma.
Alcohol consumption causes gut microflora dysbio-
sis and bacterial over-growth and ultimately increases 
gut permeability and the translocation of  LPS from the 
gut to the liver. In Kupffer cells, gut microflora derived-
LPS interacts with toll-like receptor 4 (TLR4), and pro-
inflammatory cytokines and chemokines such as TNF-α, 
IL-8, IL-17 are produced, leading to the production of  
ROS and alcohol-induced liver damage[51,52]. Interest-
ingly, activation of  TLR4 also induces Kupffer cells to 
produce hepatoprotective cytokines such as IL-6 which 
reduces hepatocyte necrosis-associated inflammation, 
albeit having proinflammatory roles, and anti-inflamma-
tory cytokines such as interleukin-10 (IL-10)[53]. How-
ever, long-term alcohol consumption may generate lipid 
peroxidation products such as malondialdehyde (MDA) 
as a result of  ROS cascades, which can modify many 
proteins linked to the adaptive immune response[54,55]. 
Patients with alcoholic liver disease have increased levels 
of  circulating antibodies against lipid peroxidation prod-
ucts and increased numbers of  T and B cells in the liver, 
which contribute to adaptive immunity activation in al-
coholic liver disease[54,55].
Gut-liver interaction
Optimal functioning of  the gut-liver axis depends on 
healthy gut integrity and mucosal microflora and a 
healthy liver; however, chronic alcohol exposure impairs 
both gut and liver health. These changes affect each oth-
er and ultimately contribute to the increased blood levels 
of  LPS, or endotoxemia, in patients with alcoholic liver 
disease. Major inducers of  chronic low-grade inflamma-
tion in alcoholic liver disease are broadly summarized 
as a direct inflammatory injury from alcohol and its me-
tabolites or an indirect inflammatory injury in response 
to LPS. The microflora-derived LPS enters systemic cir-
culation in two different ways, either via a portal vein or 
through gastrointestinal lymphatic vessels[56,57]. Most LPS 
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in the lymphatic system move through mesenteric lymph 
nodes and eventually enter the systemic circulation at the 
thoracic duct opening, whereas most LPS in the portal 
vein can be detoxified and excreted.
Alcohol can alter gut integrity and permeability in 
both direct and indirect manners. Alcohol and its me-
tabolites such as acetaldehyde can directly alter both gut 
permeability and microflora content and composition. 
Alcohol and acetaldehyde can weaken the intestinal epi-
thelial barrier, such as tight junctions between intestinal 
enterocytes. Moreover, increased gut permeability in 
alcoholic liver disease may be aggravated by increased 
expression of  inducible nitric oxide synthase (iNOS) 
and NF-κB, which, in turn, enhance the translocation of  
LPS between tight junctions of  adjacent enterocytes[58,59]. 
This increased gut permeability is also called leaky gut 
syndrome (LGS). Patients with alcoholic hepatitis com-
monly show elevated LPS levels in plasma, implicating a 
crucial role of  LPS-induced inflammation in the patho-
genesis of  alcoholic liver disease[60]. Thus, alcohol facili-
tates the translocation of  endotoxin from the intestinal 
lumen to the portal vein, thereby aggravating the risk of  
liver injury.
Individuals with chronic alcohol use are more sus-
ceptible to small intestinal bacterial overgrowth and 
dysbiosis compared to counterpart non-alcoholics or 
abstainers[61,62]. Excessive alcohol ingestion facilitates the 
overgrowth of  Gram-negative bacteria, contributing to 
increased endotoxin levels[60]. In addition, micronutri-
ent deficiency, such as zinc, is common in alcoholic liver 
disease, which adversely affects the integrity of  the intes-
tinal epithelium[63]. More recently, evidence suggests that 
increased gut permeability may be an important factor in 
the pathogenesis of  alcoholic liver disease.
As intestinal permeability increases, endotoxin and 
other bacterial toxins increase the sensitivity of  Kupffer 
cells to LPS stimulation in the liver, where increased pro-
inflammatory cytokines lead to neutrophil activation, 
increased sinusoidal permeability, generation of  ROS, 
and mitochondrial damage in the liver[64]. These cascades 
may cause systemic low-grade inflammation in addition 
to liver inflammation (Figure 1).
THERAPEUTIC TARGETS
General anti-inflammatories
The first-line therapy for alcoholic liver disease is alco-
hol abstinence with nutritional support[3,7,65]. However, 
therapeutic lifestyle changes are not easy in clinical prac-
tice and may not be sufficient for some patients. Corti-
costeroids, pentoxifylline, and TNF-α antagonist have 
been identified as therapeutic agents for severe alcoholic 
hepatitis. Among them, corticosteroids and pentoxifyl-
line are currently recommended[7]. Glucocorticoids could 
reduce immune activation by blocking cytotoxic and 
inflammatory signal pathways, and pentoxifyllin plays 
an anti-inflammatory role as a non-selective phosphodi-
esterase inhibitor and TNF-α suppressor[66]. Although 
TNF-α has been regarded as a predictor for the severity 
of  alcoholic hepatitis and TNF-α antagonist reduces 
liver damage in alcohol-fed animals, clinical trials with 
TNF-α antibody have not shown consistent results[67-69]. 
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Figure 1  Schematic of liver inflammation. LPS: Lipopolysaccharides; ROS: Reactive oxygen species; ACH: Acetaldehyde; TNF-α: Tumor necrosis factor-α; IL-1β: 
Interleukin-1β; IL-17: Interleukin-17; IL-8: Interleukin-8.
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TNF-α antibody or corticosteroids may induce a condi-
tion that causes patients to be susceptible to infections 
because of  immune suppression[7,69]. Pentoxifylline may 
be considered in patients with severe alcoholic hepatitis 
who cannot use corticosteroids[3].
Antioxidants
Antioxidants such as N-acetylcysteine have been reported 
to reduce inflammatory markers and liver fat accumula-
tion in alcohol-fed animals[49]. S-adenosylmethionine 
could increase cellular antioxidant glutathione in pa-
tients with alcoholic liver disease[70]. Betaine, precursor to 
S-adenosylmethionine, has also been reported to attenu-
ate alcoholic liver disease[71]. In clinical trials, S-adeno-
sylmethionine has shown improved survival in patients 
with less advanced liver cirrhosis[72] but has not been 
consistently effective in treating alcoholic liver disease[73]. 
Antioxidants including phytochemicals such as resvera-
trol and carotenoids are successful for treating alcohol-
fed animals, but lack convincing benefits in human 
patients[74-76]. Oxidative stress may be more pronounced 
in early stages of  alcoholic liver disease, which is found 
in most animal models, but plays a minor role in later 
stages of  alcoholic liver disease. Actually, administration 
of  antioxidants cocktail has shown inferior survival rates 
compared to corticosteroid administration in patients 
with severe alcoholic hepatitis[77].
Gut microflora and LPS pathway
The gut-liver interaction has been identified as an im-
portant interaction for liver health and prevention of  
systemic inflammation. In this regard, the modulation of  
gut microflora  and LPS pathway could be used to treat 
alcoholic liver disease[3,78,79] (Figure 2). For the former, 
probiotics and bioactive extracts may provide therapeutic 
benefit in patients with alcoholic liver disease[79,80]. In ad-
dition, non-absorbable antibiotics such as rifaximin and/
or probiotics can modify the gut microflora and help 
reduce the risk of  hepatic encephalopathy[81]. For the lat-
ter, TLR4 antagonists that modify the LPS pathway have 
been proposed as therapeutic materials for chronic liver 
disease[82].
Other therapeutic considerations
Several surrogate agents for treating alcoholic liver 
disease are being investigated. Global suppression of  
inflammatory responses could lead to undesirable side 
effects such as immune suppression. Therefore, specific 
anti-inflammatory targeting may be more promising. 
Recent studies have shown that IL-22 has hepatoprotec-
tive properties including antioxidant, anti-steatotic, and 
anti-microbial effects[83]. Moreover, the IL-22 receptor 
exists only on epithelial cells such as hepatocytes, and 
side effects that target this receptor may be minimal. 
Also, IL-8 and IL-17 have been related to neutrophil in-
filtration, TNF-α augmentation, and autoimmunity[7,84]. 
Therefore, based on the cytokine and immune cell pro-
files, specific intervention may merit serious consider-
ation to reduce the inflammatory response with minimal 
side effects.
CONCLUSION
Chronic inflammation in alcoholic liver disease and re-
lated systemic illness is mediated by a direct response to 
alcohol and an indirect inflammatory response to gut mi-
croflora-derived LPS, leading to a stronger oxidative-in-
flammatory response. In addition to alcohol abstinence, 
integrative therapeutic strategies to reduce inflammatory 
cascades may be needed to treat and prevent alcoholic 
liver disease.
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